New 52 Week High Today

Neurocrine Biosciences Inc NB3-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 8:04 AM CEST
105.04quote price arrow up+2.50 (+2.44%)
52 week range
63.54 - 105.04
Loading...
  • Open105.04
  • Day High105.04
  • Day Low105.04
  • Prev Close104.90
  • 52 Week High105.04
  • 52 Week High Date08/19/22
  • 52 Week Low63.54
  • 52 Week Low Date01/21/22

Key Stats

  • Market Cap10,098.23M
  • Shares Out95.6M
  • 10 Day Average Volume45.6
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change42.18

KEY STATS

  • Open105.04
  • Day High105.04
  • Day Low105.04
  • Prev Close104.90
  • 52 Week High105.04
  • 52 Week High Date08/19/22
  • 52 Week Low63.54
  • 52 Week Low Date01/21/22
  • Market Cap10,098.23M
  • Shares Out95.6M
  • 10 Day Average Volume45.6
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change42.18

RATIOS/PROFITABILITY

  • EPS (TTM)0.11
  • P/E (TTM)954.91
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Neurocrine Biosciences Inc

There is no recent news for this security.

Profile

MORE
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option...
William Rastetter Ph.D.
Non-Executive Independent Chairman of the Board
Kevin Gorman Ph.D.
Chief Executive Officer, Director
Matthew Abernethy CPA
Chief Financial Officer
Address
12780 El Camino Real
San Diego, CA
92130-2042
United States